arrow
S

Selma Ugurel

Bielefeld University
H指数:64
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial

体外光opheresis治疗免疫检查点抑制剂疗法所致的类固醇难治性免疫相关不良反应:一项多中心Ib/II期临床试验

2026-10-230
OAAI
Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation loss

cKIT突变黏膜黑色素瘤中伊马替尼的显著治疗获益及其随后发生的KIT突变丢失

2025-10-250
OAAI
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial

阿维鲁姆单抗联合西妥昔单抗用于不可切除的III期或IV期皮肤鳞状细胞癌患者的临床活性和安全性结果:来自AliCe这一单臂多中心DeCOG II期试验的数据

2025-09-012
PRE
Outcome of systemic therapy in patients with advanced rare skin cancers: a retrospective multicenter DeCOG study of 209 patients

晚期罕见皮肤癌患者系统性治疗的结局:一项包含209名患者的回顾性多中心DeCOG研究

2025-08-300
PREAI
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG

晚期转移性黑色素瘤的性别特异性生存率——一项DeCOG研究,涉及ADOREG多中心前瞻性皮肤癌登记研究的2032例患者。

2025-07-290
OA
Adverse effects of systemic advanced melanoma therapies-do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?

系统性晚期黑色素瘤疗法的不良反应——BRAF/MEK抑制剂是否增加肠系膜脂肪炎的发病率?

2025-05-010
OA
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg
2025-02-240
OAAI
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status

根据BRAF突变状态,脑转移的存在会对黑色素瘤一线治疗后的长期生存产生不同的影响

2025-02-140
OAAI
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
2025-01-010
OAAI
Early versus late response to PD-1-based immunotherapy in metastatic melanoma

转移性黑色素瘤对PD-1-based免疫治疗的早期与晚期反应

2024-10-010
OAAI
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1-(Triple) wild type melanomas

BRAF-、RAS-和NF1-(三重) 野生型黑色素瘤中免疫检查点抑制剂的无进展生存期和总生存期缩短

2024-09-011
OA
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

辅助治疗对皮肤黑色素瘤器官特异性复发的影响: 前瞻性DeCOG注册ADOReg的1383例患者的多中心研究

2024-07-081
OA
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

单独Anti-PD-1或联合anti-CTLA-4治疗晚期黑色素瘤肝转移患者

2024-07-011
PRE
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
2024-06-101
OAAI